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in the Republic of Moldova
Alessandra Ferrario1,2*, Nina Sautenkova3, Zinaida Bezverhni4, Rita Seicas5, Jarno Habicht6, Panos Kanavos1,2
and Vladimir Safta4Abstract
Objective: Regulation of the pharmaceutical system is a crucial, yet often neglected, component in ensuring
access to safe and effective medicines. The aim of this study was to provide an in-depth analysis of the existing
pharmaceutical regulation, including recent changes, in the Republic of Moldova.
Methods: Data from field work conducted by the World Health Organization (WHO) together with a review of
policy documents and quantitative secondary data analysis was used to achieve this aim.
Results: This analysis identified several ways in which pharmaceutical regulation affects availability of quality
medicines in the Republic of Moldova. These include lack of full implementation bioequivalence requirements for
generics registration, incomplete implementation of good manufacturing practices and no implementation of good
distribution practices, use of quality control instead of quality assurance as a method to ensure quality of
medicines, frequent change of power within the Medicines and Medical Devices Agency (MMDA) leading to lack
of long-term strategy and plans, conflict of interest between the different functions of the MMDA, the lack of
sufficient funding for the MMDA to conduct its activities and to invest in continuous training of its staff (particularly
inspectors) and very weak post-marketing control. Notably, several improvements have been recently introduced,
including a roadmap for change for the MMDA, the introduction of good manufacturing practices and the drafting
of a quality manual for the Agency.
Conclusion: Based on these findings the authors propose a set of priority actions to address existing gaps and
draw lessons learned from other countries.
Keywords: Access, Regulation, Medicines, Republic of Moldova, Former Soviet UnionIntroduction
The Republic of Moldova is a lower-middle-income
country in eastern Europe with a population of 3.5 mil-
lion (1st of January 2013, data do not include the dis-
tricts on the left side of the river Dniester and the
municipality of Bender) [1] and a gross domestic prod-
uct of US$ (current) 2,038 per capita in 2012 [2]. The
economy is heavily based on remittances from Moldovan
citizens working abroad. The country was part of the
former Soviet Union, from which it obtained indepen-
dence in 1991. Since independence, Moldova, including* Correspondence: a.ferrario@lse.ac.uk
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unless otherwise stated.its health sector, has undergone profound social, political
and economic transformations. While some reforms
were introduced in the hospital sector, much remains to
be done [3] and the most important changes so far were
compelled by the introduction of a mandatory health in-
surance system in 2004 [4]. These included strengthen-
ing of primary health care and ensuring access to a
limited number of medicines in privatised pharmacies
and selected national programmes (e.g. insulin, rare dis-
eases, tuberculosis (TB), HIV/AIDS, immunisation)[5-7].
Regulation of the pharmaceutical system is a crucial,
yet often neglected, component in ensuring access to
safe and effective medicines. While medicines financing,
selection and procurement are essential, an effective,
transparent regulatory system which manages conflict of
interest (COI) and has a well-functioning post-marketingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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igilance) is crucial to prevent entry of substandard prod-
ucts. The latter pose a threat to patients’ health and cause
wastage of resources spent on ineffective and/or unsafe
products. The importance of regulatory control in ensur-
ing equitable access to essential medicines is also included
in the World Health Organization (WHO) framework for
collective action [8].
Despite the importance of regulatory functions in en-
suring access to essential medicines, few studies are avai-
lable which explore pharmaceutical regulatory issues in
countries of the former Soviet Union. These include a
1996 review of the transparency levels across regulatory
systems worldwide which looked at Estonia and Latvia
[9], a 1998–9 review of regulatory systems worldwide in-
cluding Estonia [10], a study analysing fees charged by
regulatory authorities which included Latvia [11], a more
recent study (2008) on pharmacovigilance activities in-
cluding Belarus, the Republic of Moldova, the Russian
Federation and Ukraine [12] and two studies on the qua-
lity of information provided on websites of drug regu-
latory authorities which included Estonia, Latvia and
Lithuania [13,14].
The objectives of this study are twofold. First, to pro-
vide an in-depth analysis of the existing pharmaceutical
regulation, including recent changes, in the Republic of
Moldova by reviewing gaps and progress in the main
pharmaceutical system functions. Second, using the case
of the Republic of Moldova, this paper aims to highlight
the importance of pharmaceutical regulation in ensuring
access to quality medicines. As issues of transparency
and gaps in regulatory pharmaceutical functions are com-
mon in most low- and middle-income countries, this
paper is expected to stimulate the debate in the area and
encourage similar analysis in other countries.
Methods
This analysis is based on two in-country missions (field
work) conducted by the WHO and complemented by a
desk-review of official reports, policies and regulations,
as well as analysis of data on the number of registered
medicines vs. available medicines obtained from the na-
tional laboratory of quality control and the Medicines
and Medical Devices Agency (MMDA). The secondary
data analysis was conducted in 2013 and enabled an up-
date on findings from the missions. In 2011, the MMDA
was only responsible for pharmaceuticals and was called
Medicines Agency. In this paper, we will use the new
name of the agency (MMDA) but limit our analysis to
issues related to pharmaceuticals.
The first mission focused on procurement and supply
and was conducted by two pharmaceutical experts bet-
ween the 26th of June and the 1st of July 2011. The aim of
this field study was to analyse the centralised procurementprocess undertaken by the MMDA, through interviews
with seven management and staff members of the
MMDA. In addition, a number of structured interviews
with major stakeholders were undertaken. These included
representatives (number of interviewees in brackets) from
the Ministry of Health (3), private importers and distribu-
tors (2), a public importer (1), the Oncological Institute
(1), the central district hospital in the rayon of Calarasi
(rural, 1), a primary health care unit in the rayon of
Calarasi (2), the Republican clinic hospital (urban, 2),
a private pharmacy (1), a manufacturer (1) and an aca-
demic with expertise in pharmaceutical policy in the
Republic of Moldova (1).
The second mission was an extensive review of the en-
tire regulatory system for pharmaceuticals and was con-
ducted between the 19th and 23rd of September 2011 by
three pharmaceutical experts (including a regulator from
a European Union (EU) country). The review was per-
formed using a WHO data collection tool for the as-
sessment of regulatory systems [15,16]. Information was
collected through interviews using the WHO data col-
lection tool as a guide. Interviews were conducted with
staff members from the main regulatory institutions in
the Moldovan pharmaceutical sector and representatives
of professional associations of pharmacists. National phar-
maceutical legislation and websites of main regulatory
bodies were also reviewed. The data obtained through in-
terviews were used to validate and complement data ob-
tained from secondary sources. By using the WHO data
collection tool for the assessment of regulatory systems,
the main gaps and progress identified in the different
pharmaceutical functions were identified.
Results
There is a lack of transparency in the regulation of med-
icines. This is characterised by low access to information
on regulations and procedures for applicants and holders
of marketing authorisation and lack of clear standard
operating procedures (SOPs) for several regulatory pro-
cedures. Although various steps have been taken in re-
cent years to address these gaps, the main challenges are
the time needed to introduce the necessary legislative
changes and low human resource capacity for their im-
plementation. In fact, despite various guidelines having
been drafted, many of them have not been approved yet;
and for those approved, their implementation is often
limited due to human resource constraints. In the next
sections, we will highlight some of the main gaps and
achievements across the various regulatory functions.
Marketing authorisation (registration) of medicines
The main issue is the conflicting role of the MMDA which
is tasked to register products and also to procure them. In
a few cases, this has led to pressure from manufacturers
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requiring the demonstration of generics’ bioequivalence
with the brand product is not implemented. This is
mainly due to the lack of assessors trained in reviewing
biowavera applications for highly soluble substances and
to insufficient attention from authorities to the problem.
Good manufacturing practice (GMP) inspections are cur-
rently not a mandatory part of the registration process
and there is insufficient funding and staff trained with the
necessary training to conduct GMP inspections. Due to
low salaries and general paucity of skilled professionals in
the country, there is an insufficient number of assessors
with relevant skills in the registration department and the
national reference laboratory. In addition, the objectivity
of the decisions taken by assessors is weakened due to lack
of approved written procedures on how to assess registra-
tion applications.
Another issue is the lack of stable management or a
long-term planning process within the MMDA. In the
past two years, there have been seven different directors
and despite the staff ’s genuine commitment to raise stan-
dards and meet internationally accepted requirements,
there is very little evidence of planning and targets at the
MMDA or department level to achieve these goals. Fur-
ther, there are no COI guidelines for registration activities,
rendering the system vulnerable to vested interests. This
can be particularly problematic given the frequent use of
external experts. Moreover, the committee’s decisions are
not publicly available.
On average, about 70% to 80% of all registered medi-
cines by foreign manufacturers were actually imported
(Figure 1). However, analysis of the number of registered
products for different international non-proprietary names0
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Figure 1 Number of medicines registered by foreign
manufacturers vs. available ones. Source: Authors’ compilation
based on data from the National Laboratory of Quality Control.(INNs) suggests that in many cases more products are
registered than necessary. One of the most extreme exam-
ples is amlodipine 5 mg and 10 mg, for which, in 2012,
there were 47 and 42 products registered by foreign man-
ufacturers and 20 and 21 products imported, respectively.
A less extreme example, yet still making the case, is met-
formin 500 mg and 850 mg, for which, in 2012, there were
16 and 15 products registered by foreign manufacturers
and 5 and 5 products imported, respectively (Additional
file 1: Table S1).
In most cases when a particular medicine was only re-
gistered by foreign manufacturers, even if not all strength
were available, at least one strength per INN was im-
ported. In a few cases, mostly cancer medicines, no pro-
duct for any strength was available for a particular INN.
These included bleomycin (not imported in 2012 and
2011), busulfan (not imported in 2012), cetuximab (not
imported in 2012 and 2011), cytarabine (not imported in
2012), docetaxel (not imported in 2012), doxorubicin
hydrochloride (not imported in 2012), everolimus (cancer
indication not imported in 2012 and 2011), fludarabine
(not imported in 2012 and 2011), imatinib (not imported
in 2012 and 2011) and tamoxifen (not imported in 2012).
Unavailability of registered medicines is due to a num-
ber of reasons including unsuccessful pricing negotiations
between manufacturer and the MMDA and disincentive
on the part of distributors who may not have sufficient in-
terest in importing certain medicines because of limited
or absent demand. Low demand can be due to different
reasons like irrational prescribing, heavy promotion of
other medicines (outside the essential medicines list
(EML)) and limited promotion of essential medicines.
Finally, the financing of the MMDA is mainly based
on registration fees which is likely to provide an in-
centive to register more products that actually necessary.
Underfunding of the MMDA is a real challenge given that
registration fees have not been revised in recent years (and
thus does not take into account current expenses and
inflation rate). The issue of low availability of regis-
tered medicines has been already discussed at Ministry of
Health and some measures have been taken. Following
the recent introduction of a new regulatory requirement
in 2012, if a medicine is registered but it is not available
on the market (whether it has never been launched or it
stops being available) for three consecutive years, its regis-
tration is suspended [17].
Positive developments
Despite challenges remaining, a number of positive de-
velopments have taken place in the past two years. The
most important positive development is the introduction
of GMP guidelines, which, by December 2014, should
be implemented by all local manufacturers [18]. In July
2012, the Ministry of Health approved a new regulation
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to use the common technical document (CTD). This
document contains all information on quality, safety and
efficacy required by ICHb regulatory authorities in a stan-
dard format accepted in all ICH member countries [19].
Since January 2013, all registration dossiers are organised
and presented according to the CTD format. In addition,
the MMDA is developing an e-application system for
registration. This should help with tracking progress and
compliance with timelines. Concerning registration fees, a
draft document with a revised fee structure and add-
itional fees for activities not previously included (e.g.
fee for GMP inspection, fee for pharmacovigilance re-
lated activities, etc.) has been drafted and presented
to Government for approval in August 2013 but has
not yet been approved.
Licensing of pharmaceutical enterprises
The Licensing Chamber, a public organ under the Minis-
try of Economy is currently responsible for licensing of
pharmaceutical enterprises. This leads to fragmentation
of responsibilities between the MMDA, the Licensing
Chamber and the National Evaluation and Accreditation
Office. A transfer of the licensing function to the MMDA
was envisaged in the Medicines Agency Road Map for
2012–2014, which was approved by the Government in
April 2012. However, a draft document to modify the law
on pharmaceutical licensing activities was never approved
due to lack of support from the other ministries. In ad-
dition to not have the licensing function under a specia-
lised authority, as is the case in other countries, there are
also no pharmacists within the licensing Chamber.
On the 1st of April 2011, the Parliament approved
new rules for opening a pharmacy. The new require-
ments included a minimal distance between pharmacies
and location to be based on demographic criteria. The
law also required the Government to approve, within
three months, a national plan to determine the loca-
tion of new pharmacies based on these new criteria. The
Ministry of Economy was opposed to this national plan
and the idea of involving the Government, mainly argu-
ing that regulating the opening of new enterprises is
against free market principles. It thus provided negative
feedback on the proposed plan and proposed to instead
develop a new revision of the law to cancel all the new
criteria. The Ministry of Health developed the new draft
law which revoked the demographic criteria for pharmacy
opening locations as well as the national plan. However,
the final text currently under review by the Parliament will
likely result in the removal of all three stipulations as re-
quested by the Ministry of Economy. It is therefore still
unclear whether any new criteria on opening new phar-
macies will be introduced. Regardless, even if new criteria
are approved, complexities in access would still remainand thus further considerations could be needed. For ex-
ample, based on population criteria, the municipality of
the capital Chisinau had too many pharmacies, calling
for a moratorium on new openings. In 2012 there were
1,838 inhabitants per pharmacy in the capital rayon
(district) of Chisinau vs. an average of 4,488 inhabi-
tants per pharmacy in the other rayons. But in reality,
there were certain villages near the capital (still part
of the municipality of Chisinau) or in the recently-
built ‘microrayons’ (‘microdistricts’) where the number
of pharmacies per capita was too low. However, be-
cause the average number of pharmacies in the rayon
was too high, it was not possible to open new phar-
macies in those undersupplied areas.
Inspections and market control
There are currently no written procedures or mecha-
nisms in place to prevent regulatory capture between in-
spectors and the manufacturers or distributors that they
inspect, rendering the system vulnerable to corrupt prac-
tices. While inspectors follow available regulations, these
do not provide detailed description of the procedure to
conduct inspection (SOPs). Another important gap is
the lack of a quality management system for the inspect-
orate. Written criteria for the selection and recruitment
of inspectors are available, requiring inspectors to have
passed a specific training in inspection. Once recruited,
inspectors are not regularly trained on key areas such
GMP, good distribution practices (GDP) or good clinical
practice (GCP). Further, there is no documented process
on qualification and review to confirm the competencies
of existing inspectors.
The legislation relating to MMDA inspectors involve-
ment in pre-licensing activities is unclear and inspectors
are not involved in any stages preceding the opening of
a pharmacy. Further there is no clear legal provision des-
ignating the inspectors and their powers. As a result, in-
spectors do not have adequate powers and authority to
carry out their tasks. Another issue relates to the frag-
mentation problems mentioned previously in that only
the Licensing Chamber, and not the MMDA, can initiate
the process to revoke a license.
Due to an insufficient number of competent staff and
underfunding, the MMDA does not have resources to
inspect manufacturers with the frequency stated in the
law. Importing of low cost medicines from countries like
India and China has increased in recent years, yet there
is very limited capacity to inspect overseas suppliers and
to raise questions about the quality of the products
imported. This problem has now been addressed for re-
imbursed outpatient medicines (as explained in the next
paragraphs in the positive developments subsection) but
remains a challenge for inpatient medicines and non-
reimbursed medicines.
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scribed in the law and there are no SOPs. As a result, its
implementation does not work well in practice; for ex-
ample, suppliers who underperform are not blacklisted.
Based on doctors’ and patients’ reports, there is evidence
of the presence of low efficacy products in hospitals.
This leads to overuse, increase of dosage or to patients
having to purchase medicines, which they should receive
for free at the hospital, in private pharmacies. These cir-
cumstances are supported by findings during one of the
missions, when three different products with the same
batch number from a local manufacturer were found in
a hospital. There were also specific reports of low effect-
iveness in three different medicines: ceftazidime, an anti-
biotic imported from China which required two to three
times the standard dose to elicit the response which is
usually obtained with the standard dosage; methyl predni-
solone and betamethasone, both locally produced cortico-
steroids (from a non-GMP compliant local manufacturer)
which were reported to have no effect on patients.
Positive developments
The Republic of Moldova has already taken concrete
steps to gradually move towards GMP compliance for
imported as well as locally produced medicines. The first
step was the development and approval of GMP guide-
lines in March 2013. With the release of the new re-
imbursement list in May 2013, medicines registered in
the EU, the United States of America (USA), Canada,
Australia, or Japan (and therefore compliant with GMP)
were given preferred supplier status. This is expected to
provide a strong incentive, particularly to local manufac-
turers, to improve their manufacturing practices accord-
ing to internationally accepted GMP. Yet, in the case no
product is registered from a GMP compliant manufac-
turer, products from manufacturer with national GMP
certificates or, as a last resort, non-GMP compliant ma-
nufacturer need to be sourced. As a result of this, a
number of medicines from non-GMP compliant manu-
facturer (particularly a local manufacturer which pro-
duced the two products discussed before) are still in the
reimbursement list. For inpatient medicines, all products
tendered should comply with GMP (no specification
whether national or according to the WHO, European
Medicines Agency (EMA) or Food and Drug Adminis-
tration (FDA) criteria). The exception is psychotropic
and TB medicines for which GMP certification accor-
ding to either WHO, EMA or FDA is required. Further,
by December 2014 all local manufacturers are expected
to comply with GMP requirements. This will help to
gradually remove existing double standards within the
country as revealed during the procurement and supply
mission, where an exporting facility was found to have
voluntarily developed a quality assurance (QA) systembecause GMP compliance is required for product registra-
tion in the majority of the countries where the company
exports its products. On the contrary, a domestically-
oriented facility visited did not implement GMP (this was
the local manufacturing facility which produced the two
products mentioned previously, methyl prednisolone and
betamethasone). These efforts were complemented with
training organised for inspectors in GMP and GDP.
Improvements were also observed in the way inspec-
tions are conducted. The new law on state control of
entrepreneur activity, implemented in March 2013, in-
cludes a provision for inspection of enterprises (which
includes also pharmaceutical establishments). It defines
the principles of control and the procedures to conduct
controls. As of March 2013, the Inspectorate is publi-
shing the schedule of visits to pharmacies and ware-
houses. Moreover, the old procedure (as per the previous
legislation) to inspect the pharmaceutical facilities has
been revised; now, to visit a pharmaceutical establish-
ment the inspector has to inform the facility five days
in advance of the planned visit.
Positive developments in access to narcotics for pain
management have also occurred. Previously, the control
over the supply chain of narcotic substances used to be
too strong and fear of sanction was acting as a deterrent
for pharmacists to stock narcotics. This situation was
likely to cause problems for patients needing narcotic
painkillers, particularly in rural areas where availability is
low. In October 2012, the Ministry of Health released an
order which introduced important changes in the regu-
lation on dispensing narcotics medicines. Limits on the
quantity of medicine prescribed were removed; doctors
can now issue prescriptions for up to 30 days. Doctors
can now also prescribe additional doses before the 30
day treatment period ends, in case the patient condition
has changed.
Medicines promotion
Control on medicines promotion is an important re-
gulatory area in Moldova where doctors are known to
be heavily influenced by pharmaceutical representatives
through financial incentives. Due to very low salaries
(the average salary of a primary health care doctor was
Lei (Moldovan) 3,500 (US$ 260) in 2012) the latter can
easily double physicians’ income making this practice
very difficult to eradicate without first addressing the
problem of low wages. Beyond financial issues, lack of
training in rational prescribing and evidence-based me-
dicine make physicians easy preys of the pharmaceutical
industry. This is compounded by a lack of guidance from
the public institutions in areas such as patient education
and disease self-management which further strengthened
industry’s role and influence. For example, doctors are
required to run diabetes and hypertension schools but
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provided with patient education materials to distribute
so they rely on the pharmaceutical industry to provide
patient education materials.
There is a law on medicines (# 1409 from 1997/12/17
in the chapter VI) providing general regulation on me-
dicines’ information and advertising. The draft of regu-
lation and executive order which sets out definitions,
requirements, procedures of authorisations, prohibitions,
monitoring and complaints procedure on advertising on
medicines was presented at the beginning of 2012 to the
Ministry of Health for approval and is currently still
under discussion. The law on advertising (# 1227 from
22.06.1997) outlines the general principles for adver-
tising, including provisions on adverting medicines and
commodities. The provisions on medicine promotion
and advertising include explicit mention of the different
forms of promotion but post-marketing scientific stu-
dies, speakers’ fees and consultancies, promotion of ex-
ported medicines and restrictions and limits on gifts and
gimmicks. In addition, the provisions do not foresee an
enforcement mechanism on promotion and advertise-
ment of medicines, stating the sanctions in cases of
violation. In addition to legal gaps, there are also pro-
cedural ones. For example, while a formal complaints
procedure to report unethical promotional practices
exists, there is no evidence that this is used. Further,
despite a standard check list for pre-approval and moni-
toring is available, it does not provide SOPs and there are
gaps in the guidelines on COI for committee members or
public officials involved in the control of medicine promo-
tion activities.
A revision of the law on advertising was launched by a
group of deputies in early 2012 with a proposal to pro-
hibit advertising of medicines on television. The Govern-
ment accepted the proposal but it was refused by the
Parliament. As in other regulatory areas, a number of
other regulations remain in draft form pending approval
the Ministry of Health. These include the number of
samples pharmaceutical representatives are allowed to
provide, advertisement on the internet, enforcement rules
and training of medial or sales representatives.
Positive developments
A draft of the quality manual of MA has been developed.
Procurement
The main problem in this area is the COI between the
MMDA’s regulatory and procurement functions but
there are also various gaps in availability of guidelines,
SOPs and monitoring systems. For example, there are
no guidelines for staff on tendering processes and al-
though a general law on COI is available, there are no
specific guidelines for the procurement process. Theregulation on quality control does include requirements
for each shipment to be physically checked and samples
taken, but there are no SOPs for routine inspection of
consignments. There is a computerised management in-
formation system to report product problems during the
procurement process but it does not include quality as-
surance information. Further, there is no centralised sys-
tem to track the status of each order or to compare
quantities purchased with orders. Suppliers’ performance
is monitored at least annually but there is no system to
track suppliers’ lead-time, shelf-life, packaging of pro-
ducts and pre- and post-qualification of suppliers. It is
not straightforward to prevent underperforming sup-
pliers to take part in tenders again. In one instance, a
supplier who failed to supply the market at the agreed
conditions participated again in the tender process the
following year under a different corporate name.
While the Republic of Moldova has started using morbi-
dity data and treatment guidelines information for fore-
casting purposes, procurement is still mainly based on
previous consumption data which, as a method, has vari-
ous limitations. To be reliable, this method requires a
stable supply system with a relatively uninterrupted supply
and a full supply pipeline [20]. It also means that is for
any reasons some medicines were not procured in one
year, they will not be considered in the next forecasting
round.
National tendering is used to procure hospital medi-
cines but there are often very few bidders and sometimes
no bidder at all. In a few instances, when only one bid-
der was available in both rounds, the price in the second
tendering round was higher because the bidder took ad-
vantage of their monopoly position, forcing the MMDA
to accept the second price offer. One of the main rea-
sons is certainly the limited advertising of tenders, only
using local channels and in local language. A second pos-
sible reason goes back to the regulatory gaps identified
previously which can act as a disincentive for manufac-
turers to launch their products due to non-transparent
procedures and decision-making criteria. A third possible
reason is the underdevelopment of the regulation ground
to allow for the use of procurement methods other than
centralised tendering. For specific products with limited
market share, alternative methods such as price negoti-
ation or single source procurement from international
procurement agencies could be better suited. Finally, the
small market size and low income levels are unlikely to
make the market particularly attractive.
Although it is important from a transparency pers-
pective to have public scrutiny by another body on pro-
curement activities, the need for the Public Procurement
Agency under the Ministry of Finance to approve each
step in the procurement process and to sign all the con-
tracts has caused delays to the tendering process in the
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structive, involvement of the Anti-Corruption and Anti-
Monopoly agencies at all stages of the tendering process.
Another issue due to misplaced transparency is the
current practice of sharing bids with bidders. This prac-
tice was introduced to increase transparency, but could
prove deleterious as it may lead to collusion between
manufacturers.
Positive developments
Stating in November 2012, new regulations are in place
for use of additional public procurement methods inclu-
ding framework agreements, competitive dialogue, ne-
gotiation procedure and electronic tender. These were
already mentioned in the law but government-approved
implementation procedures were missing.
Selection
There is no consistent procedure and criteria for devel-
opment of the EML, leading to a copy and paste ap-
proach of the WHO standard EML without adjusting it
to actual needs of the country. Further, there are no ef-
forts in place to promote prescribing based on EML
among physicians. There are several gaps regarding se-
lection of committee members including the lack of a
declaration of COI, no definition of the role and responsi-
bilities of committee members and the absence of SOPs to
guide the selection committee’s decision-making process.
Positive development
The EML is currently being updated to better reflect the
epidemiological profile of the country. Further, the me-
dicines reimbursement list is under increased scrutiny
from a number of national and international partners.
This could help increasing the level of accountability
and transparency in the selection process and, hope-
fully, the extent to which such criteria are evidence-
based and following rational selection principles.
Distribution
The main gap is the lack of GDP which threatens the
maintenance of medicines’ quality during the distribu-
tion process. Although the country is planning to intro-
duce GDP guidelines, these have not yet been approved.
Further, there are no SOPs for stock management at
each level of the distribution system and it is unknown
to what extent the requirements mentioned in the law
are implemented at the warehouse level.
Quality control
Issues related to the use of quality control rather than
quality assurance measures have caused delays in avai-
lability of medicines because every imported batch had
to be tested (which is not necessary and causes workoverload for the laboratory). Further, SOPs for quality
control are largely not available and a quality policy for
the laboratory is missing. Another important gap is the
lack of a strong and well-functioning post-marketing
quality control system.
Positive development
The country has recently taken some very initial, yet pro-
mising, first steps in moving towards a risk-assessment
and quality assurance system with the introduction of a
new order on quality control of medicines. With the new
order, medicines registered by companies from the EU,
Australia, Japan, Canada or the USA are tested on a ran-
dom basis (previously all first ten batches). For medicines
registered by companies from a country other than EU,
Australia, Japan, Canada, or USA but compliant with na-
tional GMP, all the first five batches are tested (previously
all first ten batches). If the company passes all these first
five tests, all following tests are done on random (but not
risk assessment) basis. For manufacturers which are not
compliant with GMP, all batches are tested, not only the
first five. Transition to quality assurance should hopefully
help avoid delays in the future.
Import and exports
Currently, price is taken into consideration before gran-
ting an import authorisation. This practice should be
discontinued as price is not an element which should
influence the release of import permissions.
Pharmacovigilance
Low implementation of drug monitoring poses a consid-
erable risk for patients, as pre-marketing studies cover
only a very small and highly selective proportion of all
the patients who will use the drug in real life and are
therefore not large enough to capture all possible side
effects. Despite pharmacovigilance being part of the me-
dical curriculum and the availability of reporting forms
on the MMDA website, reporting is very low. This seems
to be due to a lack of understanding of the importance of
reporting, poor collaboration between medical institu-
tions, a culture of fear of making contact with authorities,
lack of pharmacovigilance responsibilities for manufac-
turers (though a new act is under development), lack, until
recently, of SOPs on pharmacovigilance activities and
unclear use of the data collected. Another issue is un-
derstaffing within the MMDA which is responsible for
pharmacovigiliance.
Positive developments
After being stable for several years, between 2004 and
2011 the number of reports to the pharmacovigilance
department at the MMDA has increased from 72 in
2011 to 180 in 2012 (of which 171 were reported to the
Ferrario et al. Journal of Pharmaceutical Policy and Practice 2014, 7:4 Page 8 of 11
http://www.joppp.org/content/7/1/4international monitoring centre in Uppsala). While these
levels are very low even for a country of the size of
Moldova, this is still an encouraging signal. In 2012, 30%
of all adverse drug reactions (ADR) reports were for
TB medicines, 25% for antiretroviral drugs (ARV), 11%
for antibiotics, 7% for medicines to induce labour and
reduce post-partum haemorrhage, 4% contraceptives, 4%
antihypertensives and the remaining percentage for other
therapeutic groups [21]. While it is not possible to com-
pare the increase in reporting by therapeutic group due to
lack of disaggregated data for previous years, most of the
ADR reports in 2012 were for TB and ARV drugs (55%
combined), which is likely to be linked with the trainings
organised by the Global Fund to fight AIDS, tuberculosis
and malaria (GF) and WHO in these two therapeutic
areas. Capacity building of health staff including manage-
ment of side effects and reporting is part of the GF sup-
port to the country in the area of TB and ARV treatment.
In addition to that, in 2011, WHO organised a training
course on pharmacovigilance for ARV drugs in Kiev and
participants (doctors involved in ARV treatment and two
specialists from the MMDA) became enthusiastic and
started sending reports. Although the increase in repor-
ting is a positive result, more efforts are needed to im-
prove reporting across all disease areas. Other positive
developments include the recent adoption by the MMDA
of the Vigi Flow system and the introduction of a fee
for pharmacovigilance activities, which were previously
funded from the general budget of the MMDA.
Discussion
Implications for access to quality medicines
Similar issues affecting the medicines regulatory system
in the Republic of Moldova have been identified in other
former Soviet Union countries. These include fragmenta-
tion of regulatory responsibilities across different agencies
and unclear coordination mechanisms, lack of sustainable
funding for the Medicines Agency, gaps in key regulatory
documents (e.g. regulations, guidelines, SOPs) which lead
to weak implementation of regulations and lack of trans-
parency in decision-making, absence of COI policy and
code of conduct for internal staff and external experts, no
or partial implementation of GMP, GDP and GCP, insuffi-
cient number of trained staff and lack of continuous train-
ing, weak to absent market control function, large gaps in
the quality management system in terms of both availabi-
lity of key documents and implementation, insufficient
staff and funding to conduct pharmacovigilance activities
and lack of strategic planning for the Medicines Agency
(unpublished observations)c,d,e,f,g,h.
This review of the Moldovan regulatory system for phar-
maceuticals highlighted several gaps but also showed that
progress has been made over time in a number of areas.
It appears, however, that more effort has been paid todeveloping regulations and less in assuring the effective-
ness of their implementation and their impact. That said,
it is important to acknowledge some of the factors which
limit the country’s ability to invest in effective implemen-
tation. These include the small population size, high levels
of emigration (among both the highly skilled and low
skilled labour force) and brain drain to the private sector
within the country, which means that there is only a very
small number of experts available (e.g. inspectors). Fur-
ther, frequent changes of power, which lead to high staff
turnover, undermine the strengthening of existing struc-
tures and systems. This is exacerbated by limited re-
sources for public agencies to perform their duties, low
salaries (which again contribute to high staff turnover but
also make physicians more prone to industry’s pressures
and incentives) and examples of nepotism within the
ruling elite of public agencies.
Despite several positive steps forward in addressing
regulatory gaps, the existing pharmaceutical legislation
remains unstructured and not harmonised with EU
requirements. In August 2013, the Ministry of Health
approved a working group for revision of medicines
legislation. A road map for 2012–2014 was also devel-
oped, which includes revision of existing regulations
to meet EU requirements. The national drug policy has
not been updated since 2002 and awareness among staff
at the MMDA seemed to be low during the regulatory
mission. Updating the policy is now one of the priorities
of the collaborative agreement 2012–2013 between WHO
Europe and the Republic of Moldova [22]. A draft of the
pharmaceutical code exists but has yet to be finalised or
implemented.
Finally, the absence of a well-functioning pharmacov-
igilance system and the presence of a weak post-market
quality control system are jeopardising patient safety and
quality of medicines in the Moldovan market. A survey
of pharmacovigilance activities in 55 low- and middle-
income countries showed that lack of budget, understaff-
ing and lack of training were among the main challenges
identified [12]. Low reporting was an issue in a number
countries, with 15 countries having received less than 100
adverse drug reactions report and 30 countries less than
1000 reports in 2007 [12]. Experience with TB and ARV
in the Republic of Moldova shows that it is possible to in-
crease the number of ADR reports through training of
health professionals. These efforts should be extended to
all disease areas by providing training in pharmacovigi-
lance to health staff (particularly doctors) and explaining,
through concrete examples, the importance of pharma-
covigilance and the positive impact of reporting so as to
motivate doctors to engage in this activity. Reporting by
patients should also be encouraged.
Gaps in regulation and lack of transparent procedures
are some of the main reasons for constant interference
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often delays the MMDA in carrying out its regulatory
functions and, together with other issues such as low
salaries, is largely responsible for the very high turnover
of the staff. Low levels of transparency in pharmaceutical
regulation are an important issue in almost all newly in-
dependent states. Low levels of transparency in regula-
tory procedures provide opportunities for people with
vested interests to influence the decision making pro-
cess. To a large extent that also explains the permanent
presence of law enforcement agencies like the Anti-
Corruption and Anti-Monopoly agencies, which are
also often used by politicians as private vehicles to
put pressure on other agencies. Further, lack of trans-
parency weakens the MMDA position, particularly in
the eyes of foreign manufacturers, and is likely to act
as a deterrent for the latter to do business in the country
and participate in tenders.
As well free from political pressure, medicines regula-
tion should also dispose of the necessary resources for
its operation [23]. Yet, financial independency and sus-
tainability of medicines regulatory authorities is an issue
in a number of developing countries. Analysis of regis-
tration fees in 34 countries suggested that for new drugs
in developing countries these fees could be raised to one
to five time the gross national income and used a policy
instrument to retain high qualified staff and reduce
registration times without turning into a disincentive for
the pharmaceutical industry [11]. Finally, it appears that
the position of the Ministry of Health is not very strong
in comparison to other ministries (e.g. the Ministry of
Agriculture which is the main driver of the economy), as
the direct and especially indirect economic impact of
good health is not monitored and used for macro political
decisions.
Conclusions
This analysis identified several ways in which pharma-
ceutical regulation affects availability of quality medi-
cines in the Republic of Moldova. These include lack of
full implementation bioequivalence requirement for ge-
nerics registration, incomplete implementation of GMP
and no implementation of GDP guidelines, use of quality
control instead of quality assurance as a method to en-
sure quality of medicines, frequent change of power
within the MMDA leading to lack of long-term strategy
and plans, COI between the different functions of the
MMDA, the lack of sufficient funding for the MMDA to
conduct its activities and to invest in continuous training
of its staff (particularly inspectors) and very weak post-
marketing control.
Based on the experience of the Republic of Moldova,
the following lessons learned can be drawn for countries
facing similar challenges. First, there is a need to addressexisting regulatory and developing SOPs where missing.
This will allow for increased levels of transparency in
the system, particularly regarding the objectivity of
decision-making processes. Second, it is important to
develop a strong quality management system based on
quality assurance and implementing GMP, GDP and GCP
to ensure the quality of the drugs reaching patients. Third,
there is a need to focus not just on developing regulations
but most importantly, to ensure that they are imple-
mented. For this to happen, key regulatory agencies need
to have sustainable funding and trained people at their
disposal, have access to continuous training opportunities
and be free from political pressures and finally enjoy stable
management which will facilitate long term planning.
Fourth, different procurement methods, depending on the
drug to be procured, may be needed to ensure availability
of essential medicines. Fifth, more efforts are needed to
strengthen pharmacovigilance systems. These include fi-
nancial and human resources but also training for doctors,
nurses and patients on the importance of pharmacovigi-
lance along with simplifying reporting requirements and
making the necessary reporting forms widely available
through different media. Sixth, this analysis showed that
there are challenges affecting access to medicines which
go beyond the pharmaceutical and health sector such as
brain drain and the low level of salaries which affects the
entire economy. Joint work with other Ministries is
required to address such challenges.Endnotes
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proval process where the efficacy and safety part of the
dossier (application) is approved based on evidence of
equivalence other than through in vivo equivalence testing
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bInternational Conference on Harmonisation of Tech-
nical Requirements for Registration of Pharmaceuticals
for Human Use (ICH).
cRaudsepp K, Polishchuk O, Bolokhovets G. Review of
the medicines regulatory system in Georgia. Tbilisi,
Georgia: World Health Organization Regional Office for
Europe, 2013.
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